SCHEMBL10080596

SCHEMBL10080596

CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(C)c3)c2cc1NC(=O)CP(=O)(OCC)OCC

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK4 Q13043 9/20 0.76
STK3 Q13188 10/20 0.69
EGFR P00533 7/20 0.67
ERBB2 P04626 5/20 0.67
STK25 O00506 1/20 0.61
MAP2K7 O14733 1/20 0.61
CHEK1 O14757 1/20 0.61
GAK O14976 1/20 0.61
EPHB6 O15197 1/20 0.61
ABCC4 O15439 1/20 0.61
MAP3K13 O43283 1/20 0.61
NUAK1 O60285 1/20 0.61
STK17B O94768 1/20 0.61
STK10 O94804 1/20 0.61
PRKD3 O94806 1/20 0.61
ABCB11 O95342 1/20 0.61
MAP4K4 O95819 1/20 0.61
CHEK2 O96017 1/20 0.61
ABL1 P00519 1/20 0.61
INSR P06213 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9948973 0.93 STK4 (0.83) STK4STK3EGFRERBB2STK25
SCHEMBL30362770 0.93 STK4 (0.83) STK4STK3EGFRERBB2STK25
SCHEMBL13826188 0.89 STK3 (0.85) STK4STK3EGFRERBB2STK25
SCHEMBL19480018 0.89 STK4 (0.73) STK4STK3EGFRERBB2STK25
SCHEMBL12309393 0.88 STK4 (0.77) STK4STK3EGFRERBB2STK25
SCHEMBL10054548 0.87 STK4 (0.76) STK4STK3EGFRERBB2STK25
SCHEMBL22419656 0.86 STK4 (1.00) STK4STK3EGFRERBB2
SCHEMBL10054547 0.86 STK4 (0.78) STK4STK3EGFRERBB2STK25
SCHEMBL13826198 0.84 STK4 (0.72) STK4STK3EGFRERBB2STK25
SCHEMBL10054550 0.84 STK4 (0.78) STK4STK3EGFRERBB2STK25

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120165352-A1 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2012-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165352-A1 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF CSNK1G3, CSNK1A1, CSNK1A1L STK4 179/4885STK3 41/4885EGFR 3299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.